ArticleNucleic acids research2026
Systemic control of HNF1B-driven redox homeostasis by N6-adenosine methylation.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Transcription factors are key regulators of gene expression and play essential roles in various diseases, yet their lack of small-molecule binding pockets makes them difficult to target with drugs. Internal RNA modifications, such as N6-methyladenosine, are widespread in mammalian cells, but how m6A-encoded epitranscriptomic information influences transcription factor activity and cellular function remains incompletely understood. Here, we demonstrate that m6A methylation directly regulates HNF1B and is essential for maintaining redox homeostasis in cancer cells. The METTL3/METTL14 methyltransferase complex deposits m6A marks within the 3'-untranslated regions of HNF1B messenger RNA (mRNA), stabilizing its expression and function. Genetic or chemical inhibition of METTL3-mediated m6A modifications disrupts HNF1B-driven glutathione metabolism, severely impairing the antioxidant capacity of cancer cells and rendering them vulnerable to oxidative stress. Notably, HNF1B loss induces oxidative stress-induced cell death across multiple cancer lineages, mirroring the metabolic dysfunction caused by m6A depletion and establishing HNF1B as a central regulator of redox defense in human cancer. By directly linking RNA modifications of a transcription factor to redox homeostasis, our findings identify the METTL3-HNF1B axis as a metabolic vulnerability in cancer and highlight its potential as a target for m6A-directed cancer therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.